Mauro Papotti
Mauro Papotti
affiliation: Università di Torino
research area(s): Cancer Biology
Course: Biomedical Sciences and Human Oncology
University/Istitution: Università di Torino
Born in Torino on July 5, 1955; married, three children.
Present position: Full Professor of Pathology, University of Turin (2000- date) and Head of Pathology (October 2003-date) St Luigi Hospital in Orbassano (Turin)
Education: High School diploma in 1974 - Liceo "C. Cavour" , final score 58/60
Medical doctor degree cum laude at the University of Turin in 1980.
Postgraduate Schools of Oncology (University of Modena, 1980-1983) and of Pathology (University of Turin, 1987-1991)
Positions. Assistant professor in the pathology division of San Giovanni Battista Hospital in Torino from January 1982 to October 1992. Associate Professor of Pathology at the University of Turin, and consultant at the S Giovanni Battista Hospital in Torino from November 1992 to September 2003.
Teaching activity
- 1983-1992: tutor for medical students, teaching anatomy and physiology at the nursing school
- 1992-2003: teaching pathology at the I Medical School in Torino,
- 1997-2003: teaching pathology at the II Medical School in Orbassano
- 2003-date: teaching pathology at the II Medical School in Orbassano
- 1994-date teaching Histopathology and Autopsy techniques at the Laboratory Technician School (III year/II semester course)
- Teaching Pathology (and cytopathology) at the Postgraduate Schools of Endocrinology (1987-date), Pathology (1992-date), Surgery III (1996-1998), Oncology (1993-date), Maxillo-Facial Surgery (1997-2002), Respiratory Medicine (2004-date), Thoracic Surgery (2005-date).
Diagnostic activity post-mortem examinations; diagnostic cytology (esfoliative and fine needle aspiration), diagnostic histopathology with special reference to pulmonary and endocrine pathology; immunohistochemistry and molecular biology techniques applied to diagnostic histocytopathology.
Other activities
- 1991-1999 Secretary and 1999-2003 President of the European School of Pathology, founded by the European Society of Pathology (with the aim of promoting updating and standardisation of diagnostic ability at the European level).
- From 1998 Supervisor of the Pathology area at the II Medical School of the University of Turin (at S. Luigi Hospital, Orbassano).
- 1997-2000 University-Hospital Committee for Health management at S. Giovanni Hospital, as member nominated by the Dean of the Medical Faculty
- 1999-2003 B2S and then GSU position for medical doctors in the Pathology division of the S. Giovanni Battista Hospital, with the responsibility of "Histocytopathologic Supervision".
- 1998-2000 "Rare Tumor " endocrine Tumors and mesothelioma working group", of the Regional Oncology Committee of the Regione Piemonte.
- Since 2003 Head of Pathology at San Luigi Hospital in Orbassano.
Research grants: CNR (Finalized Project "Neoplastic growth control" and "Oncology"), MURST/MIUR (from 1993, former "60%"), Regione Piemonte " Health-finalized Research (from 1998), San Paolo Foundation (Special Project Oncology at the San Giovanni Battista Hospital in Torino in 2002).
Editorial boards: Endocrine Pathology (USA), Pathologica (Italy), Virchows Archives (Germany), Journal of Pathology (UK), American Journal of Clinical Pathology (USA), Archives of Pathology (USA), Journal of Endocrinological Investigation (Italy).
Society memberships: International Academy of Pathology (IAP), European Society of Pathology (ESP), Endocrine Pathology Society (USA), Società Italiana di Anatomia Patologica e Citologia (SIAPEC), European NE Tumor Society (ENETS), International Association for the Study on Lung Cancer (IASLC).

Research. Application of immunocytochemistry and molecular biology techniques (in situ hybridisation, mutational analysis, Northern blot e RT-PCR) to diagnostic histo-cytopatology, to identify new markers of neoplasia and/or characterise the phenotypic profile of various human tumors and establish correlation with clinico-pathological parameters and prognosis.
Breast carcinoma with neuroendocrine differentiation, to define diagnostic and therapeutic perspectives in these tumors. Characterisation of the phenotype of such tumors with neuroendocrine markers, somatostatin receptors and clinico-pathological correlation.
Endocrine Pathology: Studies on the production of peptide hormones in various tumors and the expression of markers of neuroendocrine differentiation in pulmonary, colorectal and skin carcinomas, using immunohistochemistry and molecular biology techniques, and clinico-pathological correlates. Studies on the tissue distribution of hormonal receptors for somatostatin, prolactin, GH secretagogues, ghrelin, cortistatin. Identification of ghrelin production in neuroendocrine tumors of the gastroenteric tract, pancreas, thyroid and fetal tissues. Clinical correlation for somatostatin analog therapy.
Thyroid Pathology: investigate morphological features and phenotype of special forms of thyroid carcinoma (poorly differentiated, oxyphilic, follicualr neoplasms, hyalinising trabecular tumor, medullary carcinoma, etc), correlating the histological, cytological, hormonal expression, and cell cycle data with the clinical outcome and response to radioiodine treatment. Test the role of Galectin-3 in the cytological differential diagnosis of benign from malignant follicular tumors.
Adrenal cancer: test of diagnosticf, prognostic and predictive markers for adrenocortical tumors, and special variants.
Pulmonary Pathology: Identification of markers useful for the differential diagnosis between endocrine and non endocrine neoplasias. Investigation of prognostic and predictive markers in lung cancer
Full papers: more than 240 peer-reviewed papers, more than 220 presentations or abstracts at meetings (including presentations as invited speaker to national or international meetings and courses).
1: Porpiglia F, Fiori C, Manfredi M, Grande S, Poggio M, Bollito E, Papotti M,
Scarpa RM. (2011) Surgical margin status of specimen and oncological outcomes after laparoscopic radical prostatectomy: experience after 400 procedures. World J Urol. Jun 23. [Epub ahead of print]
2: Matarazzo P, Tuli G, Tessaris D, Verna F, Rabbone I, Lezo A, Brunati A,
Salizzoni M, Carbonaro G, Terzolo M, Reimondo G, Papotti M, Lala R. (2011) Cushing syndrome due to ectopic adrenocorticotropic hormone secretion in a 3-year-old child. J Pediatr Endocrinol Metab. 24(3-4):219-22.
3: Kumarswamy R, Mudduluru G, Ceppi P, Muppala S, Kozlowski M, Niklinski J,
Papotti M, Allgayer H. (2011) MicroRNA-30a inhibits epithelial-to-mesenchymal transition by targeting snai1 and is downregulated in non-small cell lung cancer. Int J Cancer. Jun 1. doi: 10.1002/ijc.26218. [Epub ahead of print]
4: Ceppi P, Rapa I, Lo Iacono M, Righi L, Giorcelli J, Pautasso M, Billè A,
Ardissone F, Papotti M, Scagliotti GV. (2011) Expression and pharmacological inhibition of thymidilate synthase and Src kinase in non-small cell lung cancer. Int J Cancer. May 26. doi: 10.1002/ijc.26188. [Epub ahead of print]
5: Rapa I, Saggiorato E, Giachino D, Palestini N, Orlandi F, Papotti M, Volante M. (2011) Mammalian Target of Rapamycin Pathway Activation Is Associated to RET Mutation Status in Medullary Thyroid Carcinoma. J Clin Endocrinol Metab. May 4. [Epubahead of print]
6: Pelosi G, Rossi G, Bianchi F, Maisonneuve P, Galetta D, Sonzogni A, Veronesi G, Spaggiari L, Papotti M, Barbareschi M, Graziano P, Decensi A, Cavazza A, Viale G. (2011) Immunhistochemistry by Means of Widely Agreed-Upon Markers (Cytokeratins 5/6 and 7, p63, Thyroid Transcription Factor-1, and Vimentin) on Small Biopsies of Non-small Cell Lung Cancer Effectively Parallels the Corresponding Profiling and Eventual Diagnoses on Surgical Specimens. J Thorac Oncol. Jun;6(6):1039-1049.
7: Morello V, Cabodi S, Sigismund S, Camacho-Leal MP, Repetto D, Volante M,
Papotti M, Turco E, Defilippi P. (2011) β1 integrin controls EGFR signaling and tumorigenic properties of lung cancer cells. Oncogene. Apr 11. [Epub ahead of print]
8: Volante M, Righi L, Berruti A, Rindi G, Papotti M. (2011) The pathological diagnosis of neuroendocrine tumors: common questions and tentative answers. Virchows Arch. Apr;458(4):393-402.
9: Mudduluru G, Ceppi P, Kumarswamy R, Scagliotti GV, Papotti M, Allgayer H. (2011) Regulation of Axl receptor tyrosine kinase expression by miR-34a and miR-199a/b in solid cancer. Oncogene. Jun 23;30(25):2888-99.
10: Iacono ML, Monica V, Saviozzi S, Ceppi P, Bracco E, Papotti M, Scagliotti GV. (2011) p63 and p73 isoform expression in non-small cell lung cancer and corresponding morphological normal lung tissue. J Thorac Oncol. Mar;6(3):473-81.
11: Del Vescovo V, Cantaloni C, Cucino A, Girlando S, Silvestri M, Bragantini E, Fasanella S, Cuorvo LV, Palma PD, Rossi G, Papotti M, Pelosi G, Graziano P,
Cavazza A, Denti MA, Barbareschi M. (2011) miR-205 Expression levels in nonsmall cell lung cancer do not always distinguish adenocarcinomas from squamous cell carcinomas. Am J Surg Pathol. Feb;35(2):268-75.
12: Righi L, Graziano P, Fornari A, Rossi G, Barbareschi M, Cavazza A, Pelosi G, Scagliotti GV, Papotti M. (2011) Immunohistochemical subtyping of nonsmall cell lung cancer not otherwise specified in fine-needle aspiration cytology: A
retrospective study of 103 cases with surgical correlation. Cancer. Jan 18.
doi: 10.1002/cncr.25830. [Epub ahead of print]
13: Santini D, Perrone G, Roato I, Godio L, Pantano F, Grasso D, Russo A,
Vincenzi B, Fratto ME, Sabbatini R, Della Pepa C, Porta C, Del Conte A, Schiavon G, Berruti A, Tomasino RM, Papotti M, Papapietro N, Onetti Muda A, Denaro V, Tonini G. (2011) Expression pattern of receptor activator of NFκB (RANK) in a series of primary solid tumors and related bone metastases. J Cell Physiol. Mar;226(3):780-4.
14: Righi L, Volante M, Rapa I, Tavaglione V, Inzani F, Pelosi G, Papotti M. (2010) Mammalian target of rapamycin signaling activation patterns in neuroendocrine tumors of the lung. Endocr Relat Cancer. Oct 29;17(4):977-87.
15: Volante M, Marci V, Andrejevic-Blant S, Tavaglione V, Sculli MC, Tampellini M, Papotti M. (2010) Increased neuroendocrine cells in resected metastases compared to primary colorectal adenocarcinomas. Virchows Arch. Nov;457(5):521-7.

No projects are available to students for the current accademic year.